Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017126 | 0.91 | NPSR1 (0.50) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5023445 | 0.90 | MAPT (0.46) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5023508 | 0.89 | PYGL (0.47) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5023546 | 0.87 | KDM4E (0.51) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5022953 | 0.86 | KDM4E (0.53) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5016964 | 0.86 | LMNA (0.54) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5023000 | 0.84 | MAPT (0.46) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5016978 | 0.84 | MAPT (0.52) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5016974 | 0.84 | KDM4E (0.51) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5025793 | 0.82 | KDM4E (0.53) | MAPTKDM4ESMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | claimed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | claimed |
| EP-1638556-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000301-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | claimed |
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| EP-1638556-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000301-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021478-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | MAPT 3262/4885KDM4E 2073/4885SMN1; SMN2 3860/4885 |
| US-20040266845-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | MAPT 3619/4885KDM4E 1919/4885SMN1; SMN2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.